Dr. Gandhi’s presentation, “Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer,” provides an overview of the clinical challenges of the standard-of-care treatment, available to ...

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod ...

The webinar, “Facing Today’s Challenges in Pancreatic Cancer Treatment: Understanding RenovoRx’s Trans-Arterial Micro-Perfusion Therapy Platform,” will be held on Tuesday, June 21 st at 8: ...

Results: 86 patients with NMIBC were enrolled and who received intravesical perfusion therapy combined with hematoporphyrin intravesical perfusion PDT from August 2016 to July 2024 were enrolled.

The abstract published promising pre-clinical data from the use of RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform, which aims to optimize local and targeted drug delivery in ...

The Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to bypass traditional systemic delivery methods and ensure precise therapeutic delivery to a ...

The Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to bypass traditional systemic delivery methods and ensure precise therapeutic delivery to a ...

The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025 Phase III Clinical ...

RenovoRx Inc (RNXT) reports promising sales figures and trial progress, despite challenges in commercialization and market expansion.